Flokind D

Quick links to important sections

Flokind D

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flokind D

Property Description
Active Ingredients Dutasteride, Tamsulosin hydrochloride
Form Oral Hard Capsule
Pharmacological Class 5-alpha reductase inhibitor (5-ARI) and Alpha-adrenergic antagonist (alpha1-blocker)
Mechanism Type Dual-Action Fixed-Dose Combination (FDC)
Origin Synthetic Compounds

Identity, Classification, and Composition

Flokind D is a prescription-only medicine defined by its nature as a Fixed-Dose Combination (FDC) that integrates two distinct synthetic active ingredients: Dutasteride and Tamsulosin hydrochloride. This preparation is consistently classified in pharmaceutical literature as a dual-action agent, combining two separate pharmacological classes. Dutasteride functions as a 5-alpha reductase inhibitor (5-ARI), targeting the hormonal mechanism of tissue growth, while Tamsulosin operates as an alpha-adrenergic antagonist (alpha1-blocker), which acts by blocking receptor sites in smooth muscle tissue.

Pharmaceutical Form and Dual-Action Principle

The unique pharmaceutical presentation of Flokind D is an oral hard capsule, designed for controlled release upon administration via the mouth, contrasting with liquid or other delivery methods. The composition features a distinctive internal structure to ensure stability and controlled delivery: the Dutasteride component is contained as an oily solution within a soft gelatin capsule, while the Tamsulosin component is present in modified-release granules. This sophisticated FDC structure allows for the simultaneous and optimized release of both the enzyme inhibitor and the receptor blocker, which forms the core of its synergistic dual-action principle.

General Purpose of the Combination Therapy

The strategic objective of Flokind D is to provide comprehensive support for physiological conditions in adult males related to prostate gland enlargement. By concurrently targeting the hormonal component responsible for structural tissue growth and relaxing the smooth muscle tissue that causes functional tightening, the FDC is intended to mitigate both factors. This combination therapy is often employed in situations where targeting both the prostate's volume and the associated muscle tension is considered beneficial.

Regulatory References

  1. Tamsulosin: MedlinePlus Drug Information
  2. DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE (DailyMed)

What side effects are possible with Flokind D?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Flokind D based on the reported frequency and affected system-organ class. The most common adverse reactions observed in clinical data include effects on the reproductive system, such as ejaculation disorders, impotence (erectile dysfunction), and decreased libido. Other common reactions include dizziness and breast disorders, specifically gynecomastia (enlargement) and tenderness.

Time-related patterns are noted, as symptoms of orthostatic hypotension (dizziness or fainting upon standing) may be more frequent at the initiation of treatment. Furthermore, the medicine causes a reduction in serum Prostate-Specific Antigen (PSA) concentration by approximately 50%, requiring the establishment of a new PSA baseline after six months for accurate monitoring.

Regulatory sources document several serious adverse reactions, including Syncope (fainting), Priapism (a persistent, painful erection), and clinically significant hypersensitivity reactions such as angioedema. Additionally, studies have documented an increased risk of high-grade prostate cancer (Gleason 8–10) associated with the class of medicine. Rare adverse reactions also include reports of male breast cancer.

Safety constraints and population-specific considerations are strictly defined in official labeling. The medicine is contraindicated in patients with known severe hypersensitivity, severe hepatic impairment, and in the pediatric population. Due to the risk of fetal harm to a male fetus, the capsules must not be handled by women who are pregnant or who may become pregnant. Patients scheduled for cataract or glaucoma surgery must inform their surgeon of past or current use due to the risk of Intraoperative Floppy Iris Syndrome (IFIS). Finally, patients must not donate blood until six months after the last dose.

Overdose and Emergency Response

Overdose manifestations of Flokind D, a fixed-dose combination medicine, are primarily associated with the alpha-blocker component, Tamsulosin. Regulatory documentation indicates that an acute overdose may lead to clinical signs of hypotension (low blood pressure), which is the principal documented acute physiological effect on the cardiovascular system.

In the event of a suspected overdose, regulatory authorities state that individuals must seek emergency medical attention immediately or contact a regional Poison Help line. This immediate action is mandated because severe, persistent hypotension represents the main serious outcome associated with overexposure to this type of medicine.

Management is defined as strictly symptomatic and supportive, as no specific antidote is known to reverse the effects of the drug. Officially described supportive measures include placing the patient in a supine position to help restore blood pressure. Medical professionals may consider administering intravenous fluids or using vasopressors to manage sustained hypotension. Furthermore, continuous monitoring of the patient’s renal function is required in the overdose setting. Due to the high protein-binding nature of the active components, standard procedures such as dialysis are unlikely to assist in eliminating the medicine from the body. The severity of the overdose is classified based on the degree of blood pressure instability.

Therapeutic Uses of Flokind D

What Flokind D Treats: Main Uses and Benefits

Flokind D is indicated for the management of signs and symptoms associated with Benign Prostatic Hyperplasia (BPH) in adult males. BPH, also known as an enlarged prostate gland, is a non-cancerous condition that can cause significant urinary difficulties.

Therapeutic Focus

The primary therapeutic area for this medication is the prostate and lower urinary tract. It is used to provide relief from the storage and voiding symptoms related to BPH, which can include:

  • Difficulty urinating (hesitancy or weak stream)
  • Frequent urination, particularly at night
  • Urinary urgency
  • Incomplete bladder emptying

The benefits of using Flokind D include improving overall urinary flow and reducing the discomfort caused by BPH symptoms. For some patients, continued management of BPH with this type of therapy may decrease the risk of acute urinary retention and the potential need for prostate surgery. The active components work by helping to relax muscles in the prostate and bladder neck, and by contributing to a reduction in the size of the enlarged prostate gland over time.


Quick Facts

  • Therapeutic Domain: Treatment of Benign Prostatic Hyperplasia (BPH).
  • Purpose of Treatment: To relieve bothersome urinary symptoms and improve urinary flow in men with an enlarged prostate.
  • Key Benefits: Improvement in difficulty urinating, nocturia (frequent nighttime urination), and potential reduction in risk of acute urinary retention.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Flokind D

Official regulatory guidelines strictly define the eligible population for Flokind D (Dutasteride/Tamsulosin) and list several absolute contraindications and mandatory cautions. The medicine is indicated solely for adult males with symptomatic benign prostatic hyperplasia (BPH), including the elderly.


Non-Eligibility Rules (Contraindications)

Category Regulatory Status
Gender/Age Contraindicated for women, children, and adolescents (under 18 years of age).
Hepatic Function Contraindicated in patients with severe hepatic impairment.
Hypersensitivity Contraindicated if there is a known hypersensitivity to dutasteride, tamsulosin, other 5-alpha reductase inhibitors, or any component of the formulation.
Circulatory History Contraindicated in patients with a history of orthostatic hypotension.

Conditional Use and Restrictions

Use requires caution in patients with mild to moderate hepatic impairment, as safety data in this population is limited. Caution is also advised for patients with severe renal impairment (CLcr < 10 mL/min), as these patients have not been adequately studied in clinical trials.

  • Procedural Restriction: Initiation of therapy is not recommended for patients who are scheduled to undergo cataract or glaucoma surgery due to the risk of Intraoperative Floppy Iris Syndrome (IFIS).
  • Reproductive Safety: Women who are pregnant or may become pregnant must not handle the capsules due to the risk of dermal absorption of dutasteride and potential fetal harm. Men taking Flokind D must not donate blood until at least six months after the last dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other drugs, food, and substances that are documented in official regulatory labeling for the Dutasteride/Tamsulosin combination.

Contraindicated and High-Risk Combinations

The coadministration of Flokind D is contraindicated (must be avoided) with:

  • Strong Cytochrome P450 (CYP) 3A4 Inhibitors (e.g., ketoconazole). This is due to the potential for a marked increase in the plasma levels of tamsulosin.
  • Other Alpha-Adrenergic Antagonists (alpha-blockers) because this increases the risk of symptomatic hypotension (significantly low blood pressure).
Interaction Type Examples of Interacting Substances/Classes
Enzyme-Mediated (Pharmacokinetic) Strong/Moderate Inhibitors of CYP3A4 (e.g., Erythromycin, Verapamil) and CYP2D6 (e.g., Paroxetine)
Additive Effects (Pharmacodynamic) Other Alpha-Blockers, Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., Sildenafil)

Use With Caution

Caution is advised when Flokind D is used alongside moderate inhibitors of CYP3A4, strong or moderate inhibitors of CYP2D6, or a combination of both. Concomitant use with these inhibitors can lead to increased exposure and higher drug concentrations.

Other Interaction Considerations

  • Food: This medication should be taken approximately 30 minutes after the same meal each day to ensure consistent absorption of the tamsulosin component.
  • Hepatic Impairment: The drug is contraindicated in patients with severe hepatic impairment.
  • Anticoagulants: Caution is advised when used with warfarin.

All patients should inform their healthcare provider of all prescription medications, non-prescription products, and supplements being taken.

Mechanism of Action

Flokind D is a dual-action combination product whose mechanism simultaneously targets two distinct physiological processes: the hormonal control of tissue growth and the autonomic regulation of muscle tone. The mechanism involves the complementary actions of Dutasteride and Tamsulosin.

Modulation of Androgen-Dependent Tissue Growth (Structural Action)

This core mechanism involves Dutasteride, which acts by causing the irreversible inhibition of both 5alpha-Reductase (5AR) enzyme types 1 and 2. This biochemical blockade drastically reduces the conversion of testosterone into the biologically active growth mediator 5alpha-Dihydrotestosterone (DHT). The resulting suppression of DHT removes the hormonal drive for cell proliferation, resulting in the progressive atrophy of the tissue's structural volume.

Regulation of Sympathetic Smooth Muscle Tone (Functional Action)

This complementary mechanism is delivered by Tamsulosin, a selective antagonist that blocks the alpha1A-Adrenoceptor primarily found on the smooth muscle of the structure and the bladder neck. By preventing the activation of these receptors by sympathetic nerve signals, the drug reduces the constant tension and force exerted by the muscle tissue, resulting in rapid relaxation of the muscle tissue and modulation of functional resistance.

The Dual-Action Principle

The combination targets the two primary factors regulating structure dynamics: physical size via hormonal modulation (Dutasteride) and functional tension via autonomic modulation (Tamsulosin). This synergy integrates the rapid physiological adjustment of muscle tone with a sustained, progressive structural change, targeting both static and dynamic components simultaneously.

Dosage and Administration Information

How to Use Flokind D

The administration of Flokind D follows established procedures to ensure the proper use of the dual-action fixed-dose combination.

Official Administration Guidelines

Feature Instruction Detail
Route of Administration Oral
Dosing Schedule One capsule (Dutasteride 0.5 mg / Tamsulosin 0.4 mg)
Frequency Once daily
Timing Relative to Meals Approximately 30 minutes after the same meal each day

Procedural and Population Constraints

The hard capsule must be swallowed whole with water and must not be chewed, crushed, or opened. This is a necessary requirement related to the capsule’s specialized design, which contains two distinct components—the oily dutasteride solution and the modified-release tamsulosin granules—and helps prevent irritation of the oropharyngeal mucosa.

Treatment is intended as a long-term therapy for the management of the underlying condition. For patients undergoing Prostate-Specific Antigen (PSA) monitoring, a new PSA baseline should be established after the first three to six months of administration.

No dosage adjustment is typically required for older adults or for those with moderate renal impairment. If a dose is missed, the patient should take the next scheduled dose at the usual time; the forgotten dose should not be taken later the same day, nor should the next dose be doubled.

Recent Clinical Evidence

1. Evidence for Use in Benign Prostatic Hyperplasia (BPH) Management

The research for Flokind D was studied for its use in Benign Prostatic Hyperplasia (BPH), a condition marked by functional limitations and urinary symptoms. Large-scale, long-term Randomized Controlled Trials (RCTs) was observed in adult men with a confirmed BPH diagnosis who also presented with specific clinical signs, such as moderate-to-severe urinary symptoms and an enlarged prostate gland.

The core research design compared the combination capsule against taking Tamsulosin or Dutasteride as individual treatments (monotherapies) by measuring specific study outcomes. Outcomes related to physical discomfort and daily functioning were monitored, including how symptoms change over time using standard questionnaires like the International Prostate Symptom Score (IPSS) and measures of patient-reported outcomes describing perceived discomfort like Quality of Life (QoL) scores.

Findings describe patterns observed in the studies where the combination therapy was studied for changes in IPSS and urinary flow rates. The research highlights changes measured across study periods lasting up to four years, which contributes to the evidence base for BPH research.


2. Research Focus on Disease Progression and Hard Endpoints

Research examined outcomes beyond symptom changes, specifically focusing on the long-term course of BPH. Studies monitored outcomes related to hard clinical progression events, such as the time to a patient's first episode of acute urinary retention (AUR) or the need for BPH-related surgery.

These long-term research scenarios studied populations considered to have conditions associated with acute or disruptive episodes—men with an enlarged prostate (ge 30 cm^3) and more noticeable symptoms. Studies monitored the occurrence of these outcomes over defined time intervals to examine how the measured outcomes differed across the various study groups.

Data show patterns related to the frequency of these progression events as monitored across the different study groups. Research provides context for how symptom patterns and the progression of the condition were monitored. Findings describe group patterns, and research does not determine whether an individual will respond similarly or avoid these progression events.


3. Long-Term Studies and Follow-up Duration

The evidence base for Flokind D includes data from trials that conducted follow-up durations of up to four years (48 months). This length of observation was applied in studies examining patient-reported experiences and other outcomes, including physiological strain or stress, as these may take many months to become measurable.

Studies observed how physical and functional outcomes, such as prostate volume measurements and urinary flow rates ( Q max), evolved in the observed populations over these extended periods. While four-year results are available, long-term effects are not fully established beyond the observation period of the primary trials, meaning there is limited information for long-term outcomes that continue past the four-year mark. The available data reflects the specific conditions and follow-up durations under which they were conducted.


4. Evidence in Specific Patient Populations Studied

The primary research for this combination was evaluated in a specific profile of adult male patients who had a clinical diagnosis of BPH with moderate-to-severe symptoms and a prostate volume of 30 cm^3 or greater. These were the men enrolled in the largest, longest-running studies.

Results apply only to the populations studied who met the specific inclusion criteria used in the trials. Data are still emerging, and research is ongoing for patients whose BPH is less advanced or who have less severe symptoms.

Data for certain groups remain insufficient, particularly for individuals outside of the enrolled criteria or those with certain comorbid conditions, as the largest trials often excluded men with unsuccessful prior BPH medical treatment.


5. What is Still Uncertain About Flokind D Research

While a body of evidence exists, certain research limitations should be noted. The key four-year comparative trial, which provided much of the progression data, primarily compared the combination against its two active components, Dutasteride and Tamsulosin. This means that comparative evidence is lacking against an inactive substance (placebo) over the entire extended study duration.

Furthermore, results apply only to the populations studied who met the specific enrolment criteria of an enlarged prostate and significant symptoms. Research highlights what is known—and what is still uncertain—about the consistency of findings across different BPH severity levels and patient types not fully represented in the main studies. Research continues to explore outcomes related to conditions where symptoms may vary in intensity.

Frequently Asked Questions (FAQ)

Common questions about Flokind D (FAQ)


Q: Is Flokind D the same type of medication as other drugs used for the same condition?

Regulatory documents state that Flokind D is a Fixed-Dose Combination (FDC) that includes two active ingredients belonging to different pharmacological classes: a 5-alpha reductase inhibitor (dutasteride) and an alpha-1 adrenergic antagonist (tamsulosin). This dual-action nature distinguishes it from other treatments for the same condition which may involve only a single ingredient.


Q: Are there any specific foods or drinks that interact with Flokind D?

Official information advises caution regarding the use of alcohol while taking this medication. Alcohol consumption may lower blood pressure and increase the potential for dizziness or fainting due to the tamsulosin component. Beyond alcohol, the medication is directed to be taken 30 minutes after the same meal each day for consistent absorption.


Q: Is the 'D' in the name Flokind D for a specific ingredient?

The medication is a combination of Dutasteride and Tamsulosin. The naming convention for this combination reflects the inclusion of the ingredient Dutasteride.


Q: Are the side effects of Flokind D usually temporary?

Some side effects, such as sexual dysfunction (impotence, decreased libido), may persist even after treatment has been stopped. Other effects, like dizziness or lightheadedness upon standing (orthostatic hypotension), are noted in regulatory information to be more frequent when treatment is first initiated.


Q: What are the signs of a serious allergic reaction to Flokind D?

Official documents describe serious allergic reactions, known as hypersensitivity reactions. Signs may include hives, difficulty breathing, swelling of the face, tongue, or throat (angioedema), and severe skin reactions accompanied by fever, rash, or blistering.


Q: Why do official labels sometimes warn against driving or operating machinery when starting Flokind D?

The warning is issued because the medication can cause side effects like dizziness, lightheadedness, or fainting (syncope), which may impair one’s ability to operate vehicles safely. This risk is typically related to a sudden drop in blood pressure caused by the tamsulosin component.


Q: Does Flokind D affect blood pressure readings?

Yes, the tamsulosin component can affect blood pressure. Regulatory sources confirm that the drug can cause orthostatic hypotension, which is a drop in blood pressure that may occur when moving from a sitting or lying position to a standing position.


Q: What is the black box warning (if any) associated with Flokind D in regulatory documents?

The official product labeling for the dutasteride component contains a warning regarding an increased risk of a high-grade prostate cancer (Gleason score 8–10). This specific warning is often highlighted in regulatory documentation.


Q: What are the safety classifications assigned to Flokind D by regulatory bodies?

Official classifications state that the medication is contraindicated in pregnancy. This is due to the risk of dermal absorption of dutasteride and potential harm to a male fetus.


Q: Are there different strengths or formulations of Flokind D available?

The Fixed-Dose Combination is available in a single strength capsule. This formulation contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride.


Q: Does Flokind D affect the results of routine lab work?

Yes. According to regulatory warnings, this medication reduces the serum Prostate-Specific Antigen (PSA) concentration by approximately 50%. A new PSA baseline must be established after six months to ensure accurate monitoring for prostate cancer screening purposes.


Q: How long does Flokind D typically take to start showing effects?

Symptomatic relief (functional action) may be experienced relatively quickly. However, the structural effects of the dutasteride component are gradual, with serum levels reaching the approximate target concentration after about three months of consistent daily dosing.


Q: Does Flokind D interact with herbal supplements like St. John's Wort?

Official drug interaction warnings focus on strong inhibitors and inducers of the CYP3A4 enzyme system. Because certain herbal supplements, such as St. John's Wort, can be potent CYP inducers, they may potentially affect drug concentrations.


Q: Is Flokind D known to cause fatigue or drowsiness?

Regulatory sources list central nervous system adverse reactions including dizziness, weakness (asthenia), and difficulty falling asleep or staying asleep (insomnia). Drowsiness is also a reported potential effect.


Q: Can people with pre-existing heart conditions use Flokind D?

The drug is contraindicated in patients who have a history of orthostatic hypotension (dizziness upon standing). Caution is also advised when the medication is used alongside other drugs that may lower blood pressure.


Q: Is Flokind D considered a controlled substance?

No. The medication is classified as a prescription-only drug, meaning a healthcare provider’s authorization is required, but it is not scheduled as a controlled substance by regulatory authorities.


Q: What are the inactive ingredients found in Flokind D tablets?

The official documentation includes a list of inactive ingredients present in the capsules. These include components such as gelatin, glycerin, and iron oxide colorants, among others.


Q: How does Flokind D affect normal sleep patterns?

According to the official product information, insomnia—which is difficulty falling asleep or staying asleep—is listed as a potential adverse reaction to the medication.


Q: Are there generic equivalents of Flokind D available?

Yes. The combination of the active ingredients, dutasteride and tamsulosin hydrochloride, is available as a generic Fixed-Dose Combination capsule.


Q: What information is available about stopping Flokind D and potential discontinuation effects?

Regulatory information states that the medicine should not be stopped suddenly and emphasizes the importance of continuing prescribed usage. Some side effects, especially sexual dysfunction, may persist after discontinuation, and the active drug levels can remain in the body for up to six months.


Q: Does Flokind D affect fertility in men or women?

Official studies indicate that the dutasteride component can affect male fertility by altering semen characteristics. This includes observations of reduced sperm count, semen volume, and sperm motility. The medication is not indicated for and is contraindicated in women.


Q: How quickly is the maximum benefit of Flokind D usually reached?

Maximum structural benefit from the dutasteride component is reached gradually. Steady-state serum concentrations, which are necessary for the long-term effect, are generally attained after six months of consistent daily dosing.


Q: What is the official status of Flokind D approval in major regions like the US or EU?

The Fixed-Dose Combination containing these two active ingredients is approved by major regulatory bodies, such as the FDA and EMA. It is officially indicated for the management of symptomatic benign prostatic hyperplasia (BPH).


Q: Can Flokind D change a person's mood or behavior?

Regulatory labeling lists potential central nervous system effects. These adverse reactions include reports of dizziness and confusion.


Q: What is the average half-life of Flokind D, according to pharmacokinetics data?

Because it is a combination product, it has two different half-lives. Pharmacokinetics data show the Dutasteride component has a long terminal half-life of 3 to 5 weeks. In contrast, the Tamsulosin component has a much shorter half-life of approximately 9 to 15 hours.

How should Flokind D be stored and disposed of?

How to Store and Dispose of Flokind D

The medicine must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The capsules must be kept in the original container, which should be tightly closed, and protected from heat, moisture, and light. To prevent accidental ingestion, the medication must be stored out of the reach and sight of children.

Flokind D capsules must be swallowed whole; they must not be chewed, opened, or crushed. Due to the active ingredient Dutasteride, pregnant women or women who may become pregnant must not handle the capsules. If contact occurs with a damaged capsule, the area should be washed immediately with soap and water. Disposal of unused or expired medicine must follow federal and local regulations, with drug take-back programs being a recommended method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Flokind D found in:

A-Z Index: